Advanced

Low Levels of Soluble NG2 in Cerebrospinal Fluid from Patients with Dementia with Lewy Bodies.

Nielsen, Henrietta LU ; Hall, Sara LU ; Surova, Yulia LU ; Nägga, Katarina LU ; Nilsson, Christer LU ; Londos, Elisabet LU ; Minthon, Lennart LU ; Hansson, Oskar LU and Wennström, Malin LU (2014) In Journal of Alzheimer's Disease
Abstract
The proteoglycan NG2 plays a major role in proliferation, migration, and differentiation of pericytes and NG2 cells in the brain. We have previously reported decreased NG2 levels in cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD) and a relationship between NG2 and AD biomarkers in these patients. To further investigate whether alterations in NG2 is specific to AD pathology, we measured levels of soluble NG2 (sNG2) in CSF from a patient cohort consisting of non-demented controls (n = 51), patients with Parkinson's disease (PD) (n = 61), and patients with dementia with Lewy bodies (DLB) (n = 37), two synucleinopathies whereof the latter disorder frequently coincides with amyloid-β pathology similar to AD. We found... (More)
The proteoglycan NG2 plays a major role in proliferation, migration, and differentiation of pericytes and NG2 cells in the brain. We have previously reported decreased NG2 levels in cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD) and a relationship between NG2 and AD biomarkers in these patients. To further investigate whether alterations in NG2 is specific to AD pathology, we measured levels of soluble NG2 (sNG2) in CSF from a patient cohort consisting of non-demented controls (n = 51), patients with Parkinson's disease (PD) (n = 61), and patients with dementia with Lewy bodies (DLB) (n = 37), two synucleinopathies whereof the latter disorder frequently coincides with amyloid-β pathology similar to AD. We found decreased sNG2 concentrations in DLB patients, but not in PD patients, compared to controls. Levels of sNG2 in controls and PD patients correlated to T-tau, P-tau, α-synuclein, and neurosin. Only one correlation, between sNG2 and neurosin, was found in DLB patients. Analysis of a second cohort consisting of controls (n = 23) and DLB patients (n = 31) showed that the result was reproducible, as lowered levels of sNG2 again were found in DLB patients compared to controls. We conclude that lower levels of sNG2 levels indicate a DLB-related impact on NG2 expressing cells foremost associated with neuropathology linked to accumulation of amyloid-β and not α-synuclein. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Journal of Alzheimer's Disease
publisher
IOS Press
external identifiers
  • pmid:24448788
  • wos:000333587700012
  • scopus:84901926508
ISSN
1387-2877
DOI
10.3233/JAD-132246
language
English
LU publication?
yes
id
82797bde-0042-4159-b840-665ede3ba296 (old id 4290909)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/24448788?dopt=Abstract
date added to LUP
2014-02-07 14:57:48
date last changed
2017-09-03 03:09:19
@article{82797bde-0042-4159-b840-665ede3ba296,
  abstract     = {The proteoglycan NG2 plays a major role in proliferation, migration, and differentiation of pericytes and NG2 cells in the brain. We have previously reported decreased NG2 levels in cerebrospinal fluid (CSF) from patients with Alzheimer's disease (AD) and a relationship between NG2 and AD biomarkers in these patients. To further investigate whether alterations in NG2 is specific to AD pathology, we measured levels of soluble NG2 (sNG2) in CSF from a patient cohort consisting of non-demented controls (n = 51), patients with Parkinson's disease (PD) (n = 61), and patients with dementia with Lewy bodies (DLB) (n = 37), two synucleinopathies whereof the latter disorder frequently coincides with amyloid-β pathology similar to AD. We found decreased sNG2 concentrations in DLB patients, but not in PD patients, compared to controls. Levels of sNG2 in controls and PD patients correlated to T-tau, P-tau, α-synuclein, and neurosin. Only one correlation, between sNG2 and neurosin, was found in DLB patients. Analysis of a second cohort consisting of controls (n = 23) and DLB patients (n = 31) showed that the result was reproducible, as lowered levels of sNG2 again were found in DLB patients compared to controls. We conclude that lower levels of sNG2 levels indicate a DLB-related impact on NG2 expressing cells foremost associated with neuropathology linked to accumulation of amyloid-β and not α-synuclein.},
  author       = {Nielsen, Henrietta and Hall, Sara and Surova, Yulia and Nägga, Katarina and Nilsson, Christer and Londos, Elisabet and Minthon, Lennart and Hansson, Oskar and Wennström, Malin},
  issn         = {1387-2877},
  language     = {eng},
  month        = {01},
  publisher    = {IOS Press},
  series       = {Journal of Alzheimer's Disease},
  title        = {Low Levels of Soluble NG2 in Cerebrospinal Fluid from Patients with Dementia with Lewy Bodies.},
  url          = {http://dx.doi.org/10.3233/JAD-132246},
  year         = {2014},
}